No cell lines used in this study were found in the database of commonly misidentified cell lines (maintained by ICLAC and NCBI Biosample). Ins1E cells were regularly tested negative for
mycoplasma contamination (Eurofins) and their identity confirmed by functional insulin secretion assays, qPCR, immunofluorescence stainings and western blots for β-cell marker mRNAs/proteins. Ins1E cells (including knockout cell lines) were cultivated in
RPMI 1640 with 10% FCS, 2 mM Glutamax, 10 mM HEPES, 2 mM Na-pyruvate, 0.18 mM 2-mercaptoethanol and 100 U ml
−1 penicillin–streptomycin (all Thermo Fisher). CRISPR knockout lines were engineered according to a double single guide RNA (sgRNA) strategy
29 using the PX459 plasmid or a modified PX458 plasmid
55 (link). pSpCas9(BB)−2A-GFP (PX458) and pSpCas9(BB)−2A-Puro (PX459) were a gift from Feng Zhang (Addgene plasmids #48138 and #48139). Positive clones were enriched using either puromycin selection or FACS sorting using a
FACSAria III (BD Biosciences, running FACSDiva software) or a
Cytoflex SRT (Beckman Coulter, running CytExpert software). Monoclonal colonies were grown until near confluency in a 96-well plate, and after passaging, knockout was confirmed using deletion PCR, qPCR and/or immunoblot. At least three monoclonal cell lines were pooled before experiments
56 (link), if not denoted otherwise in the figure legends.
Griess K., Rieck M., Müller N., Karsai G., Hartwig S., Pelligra A., Hardt R., Schlegel C., Kuboth J., Uhlemeyer C., Trenkamp S., Jeruschke K., Weiss J., Peifer-Weiss L., Xu W., Cames S., Yi X., Cnop M., Beller M., Stark H., Kondadi A.K., Reichert A.S., Markgraf D., Wammers M., Häussinger D., Kuss O., Lehr S., Eizirik D., Lickert H., Lammert E., Roden M., Winter D., Al-Hasani H., Höglinger D., Hornemann T., Brüning J.C, & Belgardt B.F. (2022). Sphingolipid subtypes differentially control proinsulin processing and systemic glucose homeostasis. Nature Cell Biology, 25(1), 20-29.